Condition
Alport Syndrome, X-Linked
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Enrolling By Invitation1
Completed1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07523581Phase 2Not Yet RecruitingPrimary
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
NCT04937907Phase 2CompletedPrimary
Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)
NCT03655223Enrolling By Invitation
Early Check: Expanded Screening in Newborns
Showing all 3 trials